Navigation Links
Medical Journal Publishes First Large-Scale Survey Revealing,Experiences of IPF Patients

CPF-Funded Research Manuscript Appears in Peer-Review Journal Respiratory Medicine

SAN JOSE, Calif., March 21, 2007 /PRNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced a summary manuscript from its Basic Research Questionnaire, considered one of the largest databases of information on patients suffering from idiopathic pulmonary fibrosis (IPF) in the United States, was published in Respiratory Medicine. The publication is an internationally-renowned, peer-reviewed journal devoted to the rapid publication of clinically-relevant respiratory medicine research. This manuscript represents the first large-scale survey of patient experiences and perceptions regarding the diagnosis and treatment of IPF published to date.

The paper, entitled "Patient Experiences with Pulmonary Fibrosis," was authored by Harold Collard, M.D. (University of California, San Francisco), Marvin Schwarz, M.D. (University of Colorado Health Sciences Center), Gregory Tino, M.D. (University of Pennsylvania Medical Center), Paul Noble, M.D. (Duke University Medical Center), Mark Shreve (CPF), and Maureen Michaels and Bruce Carlson (Michaels Opinion Research, Inc.).

The manuscript has been published ahead of print and is available on PubNet, or by visiting the CPF Web page at http://www.coalitionforpf.org/Healthcare/resources.asp . The manuscript is cited as: Collard HR, et al. Patient experiences with pulmonary fibrosis. Respir Med (2006), doi:10.1016/j.rmed.2006.10.002.

The manuscript focuses on the issues of patient education and resources. A survey of 52 defined-choice and open-ended questions regarding the diagnosis and management of pulmonary fibrosis was delivered. Two-thirds of the total 1,448 respondents reported a clear lack of information and resources on pulmonary fibrosis at the time of diagnosis. Less tha n half of respondents reported they felt well-informed about treatment options, the role of supplemental oxygen, pulmonary rehabilitation and transplantation. These results suggest there remains a substantial need for improved patient education regarding the diagnosis and management of pulmonary fibrosis.

"Representing the viewpoint of the patients we serve, and delivering programs and services to meet their needs, remains central to our mission," said Mark A. Shreve, chief executive officer of the CPF. "This research clearly shows that we can all be doing more to help IPF patients and their families."

Overall, more than 2,000 patients and families have completed the Basic Research Questionnaire. It is managed by Michaels Opinion Research, Inc. ( http://www.michealsresearch.com ), an independent research firm based in New York.

Funding for this program is provided through private gifts from the DuBrul Family Fund and from Helen and Michael Galvin in memory of their family members who have passed away from IPF.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, which is the most prevalent of a classification of lung disorders known as interstitial lung diseases (ILD's). There is currently no known cause or cure for IPF, nor is there an FDA-approved treatment. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose, and an estimated two- thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF ), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.

CONTACT: Teresa R. Geiger, Coalition for Pulmonary Fibrosis,+1-303-521-4080, tgeiger@coalitionforpf.org

Web site: http://www.coalitionforpf.org/http://www.coalitionforpf.org/Healthcare/resources.asp/http://www.michealsresearch.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
11. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):